Boosted atazanavir and Truvada [tenofovir disoproxil fumarate + emtricitabine] given once-daily (BATON study): A phase 4 study of safety, efficacy and adherence in HIV infected, antiretroviral naive subjects treated with a simple once-daily regimen

Trial Profile

Boosted atazanavir and Truvada [tenofovir disoproxil fumarate + emtricitabine] given once-daily (BATON study): A phase 4 study of safety, efficacy and adherence in HIV infected, antiretroviral naive subjects treated with a simple once-daily regimen

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jan 2013

At a glance

  • Drugs Atazanavir (Primary) ; Emtricitabine (Primary) ; Ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BATON
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Dec 2007 Status changed from in progress to completed.
    • 19 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top